

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Interventional Procedures Advisory Committee

Minutes of the Committee's 181<sup>st</sup> meeting held at 10:30 on Thursday 09<sup>th</sup> May 2019 at NICE, 10 Spring Gardens, London, SW1A 2BU

#### **PRESENT:**

Dr Tom Clutton-Brock (Chair)  
Dr Wael Agur  
Mr Jonathan Anderson  
Dr Jonathan Bell  
Mrs Sally Brearley  
Dr Chris Carroll  
Dr Andrew Cook (Vice Chair)  
Mrs Suzanne Halliday  
Mrs Rosemary Harris  
Mr Colin Howie  
Mr Tim Jackson  
Dr Tim Kinnaird  
Dr Neil McGuire  
Miss Karen Nugent  
Professor Frank Smith  
Dr Dhiraj Tripathi (arrived at 10:52)

#### **In Attendance**

##### **NICE Staff:**

Kevin Harris – PD and Consultant Clinical Advisor, IPP  
John Powell, Consultant Clinical Advisor, IPP  
Lakshmi Mandava, Analyst, IPP  
Helen Gallo, Senior Analyst, IPP  
Xia Li, Analyst, IPP  
Tika Ram – Analyst IPP  
Rebecca Willans - Specialty Public Health Registrar  
Deonee Stanislaus, Coordinator, IPP  
Azad Hussain, Administrator, IPP  
Ria Skelton, Senior Medical Editor, NICE  
Helen Crosbie, PIP, NICE  
Mrs Bijal Joshi, Programme Manager, IPP

##### **Specialist Advisors:**

Mr Barrie White – Specialist Advisor (IP1553)  
Dr Katy Sinka – Specialist Advisor (IP1553)

##### **Apologies:**

Mr Mahmoud Elfar

**Confirmed**

Mr Anthony Hatswell  
Mr Malcolm Lowe-Lauri  
Mr Kieran Murphy  
Dr Peter Murphy  
Dr James Tysome

*Note: The order in which the Committee took items of business at the meeting might differ from the agenda*

**Meeting started: 10:35**

### **Introduction to the meeting**

The Chairman welcomed the Committee Members. The Chairman also welcomed:

- Tika Ram; Technical Analyst in the Interventional Procedures Programme
- Barrie White; Specialist Advisor for IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease
- Katy Sinka; Specialist Advisor for IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease

The Chairman also welcomed the members of the public and company representatives present at the meeting.

### **Code of conduct for members of the public and company representatives attending the meeting**

The Chairman outlined the code of conduct for the members of the public and company representatives attending the meeting.

#### **1. Any Other Business**

None

#### **2. Minutes of previous meeting**

Rosemary pointed out that in the previous minutes Kieran Murphy was inserted as present at the meeting where in fact Kieran was absent. This error will be corrected.

#### **3. Matters arising**

None

#### **4. Agenda changes**

The chairman informed the Committee that, the order of the agenda will be as follows IP1553, IP1019/2, IP1135, IP1723, IP1727.

**5. NICE's Advisory Body guide to declaring a conflict of interest**

The Chairman drew the Committee's attention to NICE's advisory body quick guide for declaring conflicts of interest.

**6. Newly Notified Procedures**

**IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease**

**The discussion on IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease started at 10:46**

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock and Katy Sinka and Barrie White

The Chairman declared a Part Two and members of the public as well as left the meeting at 11:26

**The Committee made its provisional recommendations on the safety and efficacy of the procedure.**

**The discussion on IP1553 Patient safety and reduction of risk of transmission of Creutzfeldt–Jakob disease ended at 13:35.**

The members of the public as well as company representatives returned at 14:00

**IP1019/2 Irreversible electroporation for treating primary liver cancer**

**The discussion on IP1019/2 Irreversible electroporation for treating primary liver cancer started at 14:02**

**Company representatives from AngioDynamics were present for this topic.**

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tim Kinnaird and John Bell

The Chairman declared a Part Two and members of the public as well as company representatives left the meeting at 14:28

**Confirmed**

**The Committee made its provisional recommendations on the safety and efficacy of the procedure.**

**The discussion on IP1019/2 Irreversible electroporation for treating primary liver cancer ended at 14:59**

The company representatives returned at 15:01

**IP1135 Midcarpal hemiarthroplasty for wrist arthritis**

**The discussion on IP1135 Midcarpal hemiarthroplasty for wrist arthritis started at 15:02**

**Company representatives from Lavender Medical Ltd. were present for this topic.**

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Karen Nugent and Colin Howie

The Chairman declared a Part Two and company representatives left the meeting at 15:16

**The Committee made its provisional recommendations on the safety and efficacy of the procedure.**

**The discussion on IP1135 Midcarpal hemiarthroplasty for wrist arthritis ended at 15:22**

The company representatives returned at 15:23

**7. Public Consultation comments**

**IP1723 Transurethral laser ablation for recurrent non-muscle invasive bladder cancer**

**The discussion on IP1723 Transurethral laser ablation for recurrent non-muscle invasive bladder cancer started at 15:23**

**Company representatives from Promed were present for this topic.**

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Tom Clutton-Brock

**The Committee considered the consultation comments**

**Confirmed**

The Chairman declared a Part Two and company representatives left the meeting at 15:29

**The Committee upheld its decision on the safety and efficacy of the procedure.**

**The discussion on IP1723 Transurethral laser ablation for recurrent non-muscle invasive bladder cancer ended at 15:32**

No members of public or company present from this point onwards.

**IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids**

**The discussion on IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids started at 15:33**

No conflicts of interest were declared for this procedure

The Committee was reminded that equalities issues was discussed at the brief stage.

Introduced by Wael Agur

**The Committee considered the consultation comments**

**The Committee upheld its decision on the safety and efficacy of the procedure.**

**The discussion on IP1727 Ultrasound-guided high-intensity transcutaneous focused ultrasound for symptomatic uterine fibroids ended at 15:40**

## **9. Other meeting matters**

None

## **10. Date of the next meeting**

The 182<sup>nd</sup> meeting of the Interventional Procedures Advisory Committee will be held on Thursday 13<sup>th</sup> June 2019 and will start promptly at 10:30. The meeting will be held at NICE, 10 Spring Gardens, London, SW1A 2BU

The meeting ended at 15:40